We are live on ! Find out more
VKTX icon

Viking Therapeutics

10 hedge funds and large institutions have $66K invested in Viking Therapeutics in 2016 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

43% more funds holding

Funds holding: 7 → 10 (+3)

0.22% less ownership

Funds ownership: 0.46% → 0.24% (-0.22%)

43% less capital inflows, than outflows

Capital inflows: $40.8K | Capital outflows: $72K

Holders
10
Holders Change
+3
Holders Change %
+42.86%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
1
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

VKTX Hedge Fund Activity: Q1 2016 in Review

10 of the 3,768 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q1 2016, worth a combined $66K — down 58% from $158K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new VKTX positions and 3 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $26.2K. The largest seller was Goldman Sachs, exiting entirely with an estimated $44K sold.

  • 10 institutional investors held Viking Therapeutics (VKTX) as of Q1 2016, up from 7 in Q4 2015.
  • Funds reported $66K of Viking Therapeutics stock for Q1 2016, down 58% quarter-over-quarter.
  • 6 funds opened new Viking Therapeutics positions in Q1 2016 and 3 closed out, a net change of +3 holders.
  • The largest Viking Therapeutics buyer in Q1 2016 was Citadel Advisors, an estimated $26.2K added.
  • The largest Viking Therapeutics seller in Q1 2016 was Goldman Sachs, an estimated $44K sold.

Based on aggregated 13F filings for Q1 2016.